Variable | Training set | Validation set | |||||
---|---|---|---|---|---|---|---|
Viremia (n = 23) | Control (n = 24) | P values | Viremia (n = 36) | Control (n = 36) | P values | ||
Age, yearsa | 44.1 ± 4.0 | 51.9 ± 3.6 | 0.15‡ | 52.8 ± 3.3 | 49.7 ± 3.2 | 0.50‡ | |
Sex, n |  |  | 0.19§ |  |  | 0.48§ | |
 Male | 9 (39.1%) | 14 (58.3%) |  | 19 (52.8%) | 16 (44.4%) |  | |
 Female | 14 (60.9%) | 10 (41.7%) |  | 17 (47.2%) | 20 (55.6%) |  | |
HCMV DNA Levelb | 1920 (1100, 3680) | – |  | 1995 (795.5, 9995) | – |  | |
Anti-HCMV IgG (IU/mL)a | 1.59 ± 0.16 | 1.74 ± 0.19 | 0.57 ‡ | 1.94 ± 0.16 | 1.63 ± 0.15 | 0.17‡ | |
Anti-HCMV IgM, n | |||||||
 Positive | 0 (0%) | 0 (0%) |  | 0 (0%) | 0 (0%) |  | |
 Negative | 23 (100%) | 24 (100%) |  | 36 (100%) | 36 (100%) |  | |
HCV, n | |||||||
 Positive | 0 (0%) | 0 (0%) |  | 0 (0%) | 0 (0%) |  | |
 Negative | 23 (100%) | 24 (100%) |  | 36 (100%) | 36 (100%) |  | |
EB, n |  |  | 0.19§ |  |  | 0.47§ | |
 Positive | 11 (47.8%) | 16 (66.7%) |  | 13 (36.1%) | 16 (44.4%) |  | |
 Negative | 12 (52.2%) | 8 (33.3%) |  | 23 (63.9%) | 20 (55.6%) |  | |
HIV, n | |||||||
 Positive | 0 (0%) | 0 (0%) |  | 0 (0%) | 0 (0%) |  | |
 Negative | 23 (100%) | 24 (100%) |  | 36 (100%) | 36 (100%) |  | |
Leukemia, n |  |  | 0.61§ |  |  | 1§ | |
 Yes | 7 (30.4%) | 9 (37.5%) |  | 13 (36.1%) | 13 (36.1%) |  | |
 No | 16 (69.6%) | 15 (62.5%) |  | 23 (63.9%) | 23 (63.9%) |  | |
Autoimmune diseases, n |  |  | 0.81§ |  |  | 0.44§ | |
 Yes | 6 (26.1%) | 7 (29.2%) |  | 9 (25%) | 12 (33.3%) |  | |
 No | 17 (73.9%) | 17 (70.8%) |  | 27 (75%) | 24 (66.7%) |  |